Loading…

Challenges in cancer vaccine development for hepatocellular carcinoma

Summary Hepatocellular carcinoma (HCC) is the most common liver malignancy, representing the third and fifth leading cause of death from cancer worldwide in men and women, respectively. The main risk factor for the development of HCC is the hepatitis B and C virus (HBV and HCV) infection; non-viral...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2013-10, Vol.59 (4), p.897-903
Main Authors: Buonaguro, Luigi, Petrizzo, Annacarmen, Tagliamonte, Maria, Tornesello, Maria Lina, Buonaguro, Franco M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273
cites cdi_FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273
container_end_page 903
container_issue 4
container_start_page 897
container_title Journal of hepatology
container_volume 59
creator Buonaguro, Luigi
Petrizzo, Annacarmen
Tagliamonte, Maria
Tornesello, Maria Lina
Buonaguro, Franco M
description Summary Hepatocellular carcinoma (HCC) is the most common liver malignancy, representing the third and fifth leading cause of death from cancer worldwide in men and women, respectively. The main risk factor for the development of HCC is the hepatitis B and C virus (HBV and HCV) infection; non-viral causes (e.g., alcoholism and aflatoxin) are additional risk factors. HCC prognosis is generally poor because of the low effectiveness of available treatments and the overall 5-year survival rate is approximately 5–6%. In this framework, immunotherapeutic interventions, including cancer vaccines, may represent a novel and effective therapeutic tool. However, only few immunotherapy trials for HCC have been conducted so far with contrasting results, suggesting that improvements in several aspects of the immunotherapy approaches need to be implemented. In particular, identification of novel specific tumor antigens and evaluation of most advanced combinatorial strategies could result in unprecedented clinical outcomes with great beneficial effect for HCC patients. The state of the art in immunotherapy strategies for HCC and future perspectives are reported in the present review.
doi_str_mv 10.1016/j.jhep.2013.05.031
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1434744581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827813003632</els_id><sourcerecordid>1434744581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273</originalsourceid><addsrcrecordid>eNp9kU2L1TAYhYMoznX0D7iQLt20vvlsCyLIZfyAARfqOqTpGyc1ba5Je2H-vSl3dOHCVTbPOUmeQ8hLCg0Fqt5MzXSHp4YB5Q3IBjh9RA5UAdSgBH1MDgXq6o613RV5lvMEABx68ZRcMd5SQWV7IDfHOxMCLj8wV36prFkspupsrPULViOeMcTTjMtauZiqcp1Zo8UQtmBSoVPB4myekyfOhIwvHs5r8v3Dzbfjp_r2y8fPx_e3tRVSrvUgGYDF3vZMWGMH29PROWhHNG6gsmuxZ2YcpBjBmUFxyqlyg3KqV0L1rOXX5PWl95Tirw3zqmef9-eYBeOWNRVctELIjhaUXVCbYs4JnT4lP5t0rynoXZ-e9K5P7_o0SF30ldCrh_5tmHH8G_njqwBvLwCWX549Jp2tx-Js9Antqsfo_9__7p-4DX7x1oSfeI95iltaij9NdWYa9Nd9wH0_yst0ijP-G9b5llA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1434744581</pqid></control><display><type>article</type><title>Challenges in cancer vaccine development for hepatocellular carcinoma</title><source>Elsevier</source><creator>Buonaguro, Luigi ; Petrizzo, Annacarmen ; Tagliamonte, Maria ; Tornesello, Maria Lina ; Buonaguro, Franco M</creator><creatorcontrib>Buonaguro, Luigi ; Petrizzo, Annacarmen ; Tagliamonte, Maria ; Tornesello, Maria Lina ; Buonaguro, Franco M</creatorcontrib><description>Summary Hepatocellular carcinoma (HCC) is the most common liver malignancy, representing the third and fifth leading cause of death from cancer worldwide in men and women, respectively. The main risk factor for the development of HCC is the hepatitis B and C virus (HBV and HCV) infection; non-viral causes (e.g., alcoholism and aflatoxin) are additional risk factors. HCC prognosis is generally poor because of the low effectiveness of available treatments and the overall 5-year survival rate is approximately 5–6%. In this framework, immunotherapeutic interventions, including cancer vaccines, may represent a novel and effective therapeutic tool. However, only few immunotherapy trials for HCC have been conducted so far with contrasting results, suggesting that improvements in several aspects of the immunotherapy approaches need to be implemented. In particular, identification of novel specific tumor antigens and evaluation of most advanced combinatorial strategies could result in unprecedented clinical outcomes with great beneficial effect for HCC patients. The state of the art in immunotherapy strategies for HCC and future perspectives are reported in the present review.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2013.05.031</identifier><identifier>PMID: 23714157</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Active immunotherapy ; Antigens, Neoplasm - immunology ; Cancer vaccine ; Cancer Vaccines - immunology ; Cancer Vaccines - therapeutic use ; Carcinoma, Hepatocellular - immunology ; Carcinoma, Hepatocellular - therapy ; Combined Modality Therapy ; Female ; Gastroenterology and Hepatology ; Hepatocellular carcinoma ; Humans ; Liver Neoplasms - immunology ; Liver Neoplasms - therapy ; Male ; Metronomic chemotherapy ; Molecular Targeted Therapy ; Tumor antigen discovery ; Tumor Microenvironment - immunology ; Vaccination - methods ; Vaccination - trends</subject><ispartof>Journal of hepatology, 2013-10, Vol.59 (4), p.897-903</ispartof><rights>European Association for the Study of the Liver</rights><rights>2013 European Association for the Study of the Liver</rights><rights>Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273</citedby><cites>FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23714157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buonaguro, Luigi</creatorcontrib><creatorcontrib>Petrizzo, Annacarmen</creatorcontrib><creatorcontrib>Tagliamonte, Maria</creatorcontrib><creatorcontrib>Tornesello, Maria Lina</creatorcontrib><creatorcontrib>Buonaguro, Franco M</creatorcontrib><title>Challenges in cancer vaccine development for hepatocellular carcinoma</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Summary Hepatocellular carcinoma (HCC) is the most common liver malignancy, representing the third and fifth leading cause of death from cancer worldwide in men and women, respectively. The main risk factor for the development of HCC is the hepatitis B and C virus (HBV and HCV) infection; non-viral causes (e.g., alcoholism and aflatoxin) are additional risk factors. HCC prognosis is generally poor because of the low effectiveness of available treatments and the overall 5-year survival rate is approximately 5–6%. In this framework, immunotherapeutic interventions, including cancer vaccines, may represent a novel and effective therapeutic tool. However, only few immunotherapy trials for HCC have been conducted so far with contrasting results, suggesting that improvements in several aspects of the immunotherapy approaches need to be implemented. In particular, identification of novel specific tumor antigens and evaluation of most advanced combinatorial strategies could result in unprecedented clinical outcomes with great beneficial effect for HCC patients. The state of the art in immunotherapy strategies for HCC and future perspectives are reported in the present review.</description><subject>Active immunotherapy</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Cancer vaccine</subject><subject>Cancer Vaccines - immunology</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Carcinoma, Hepatocellular - immunology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Gastroenterology and Hepatology</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver Neoplasms - immunology</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Metronomic chemotherapy</subject><subject>Molecular Targeted Therapy</subject><subject>Tumor antigen discovery</subject><subject>Tumor Microenvironment - immunology</subject><subject>Vaccination - methods</subject><subject>Vaccination - trends</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kU2L1TAYhYMoznX0D7iQLt20vvlsCyLIZfyAARfqOqTpGyc1ba5Je2H-vSl3dOHCVTbPOUmeQ8hLCg0Fqt5MzXSHp4YB5Q3IBjh9RA5UAdSgBH1MDgXq6o613RV5lvMEABx68ZRcMd5SQWV7IDfHOxMCLj8wV36prFkspupsrPULViOeMcTTjMtauZiqcp1Zo8UQtmBSoVPB4myekyfOhIwvHs5r8v3Dzbfjp_r2y8fPx_e3tRVSrvUgGYDF3vZMWGMH29PROWhHNG6gsmuxZ2YcpBjBmUFxyqlyg3KqV0L1rOXX5PWl95Tirw3zqmef9-eYBeOWNRVctELIjhaUXVCbYs4JnT4lP5t0rynoXZ-e9K5P7_o0SF30ldCrh_5tmHH8G_njqwBvLwCWX549Jp2tx-Js9Antqsfo_9__7p-4DX7x1oSfeI95iltaij9NdWYa9Nd9wH0_yst0ijP-G9b5llA</recordid><startdate>20131001</startdate><enddate>20131001</enddate><creator>Buonaguro, Luigi</creator><creator>Petrizzo, Annacarmen</creator><creator>Tagliamonte, Maria</creator><creator>Tornesello, Maria Lina</creator><creator>Buonaguro, Franco M</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20131001</creationdate><title>Challenges in cancer vaccine development for hepatocellular carcinoma</title><author>Buonaguro, Luigi ; Petrizzo, Annacarmen ; Tagliamonte, Maria ; Tornesello, Maria Lina ; Buonaguro, Franco M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Active immunotherapy</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Cancer vaccine</topic><topic>Cancer Vaccines - immunology</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Carcinoma, Hepatocellular - immunology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Gastroenterology and Hepatology</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver Neoplasms - immunology</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Metronomic chemotherapy</topic><topic>Molecular Targeted Therapy</topic><topic>Tumor antigen discovery</topic><topic>Tumor Microenvironment - immunology</topic><topic>Vaccination - methods</topic><topic>Vaccination - trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buonaguro, Luigi</creatorcontrib><creatorcontrib>Petrizzo, Annacarmen</creatorcontrib><creatorcontrib>Tagliamonte, Maria</creatorcontrib><creatorcontrib>Tornesello, Maria Lina</creatorcontrib><creatorcontrib>Buonaguro, Franco M</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buonaguro, Luigi</au><au>Petrizzo, Annacarmen</au><au>Tagliamonte, Maria</au><au>Tornesello, Maria Lina</au><au>Buonaguro, Franco M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Challenges in cancer vaccine development for hepatocellular carcinoma</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2013-10-01</date><risdate>2013</risdate><volume>59</volume><issue>4</issue><spage>897</spage><epage>903</epage><pages>897-903</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><abstract>Summary Hepatocellular carcinoma (HCC) is the most common liver malignancy, representing the third and fifth leading cause of death from cancer worldwide in men and women, respectively. The main risk factor for the development of HCC is the hepatitis B and C virus (HBV and HCV) infection; non-viral causes (e.g., alcoholism and aflatoxin) are additional risk factors. HCC prognosis is generally poor because of the low effectiveness of available treatments and the overall 5-year survival rate is approximately 5–6%. In this framework, immunotherapeutic interventions, including cancer vaccines, may represent a novel and effective therapeutic tool. However, only few immunotherapy trials for HCC have been conducted so far with contrasting results, suggesting that improvements in several aspects of the immunotherapy approaches need to be implemented. In particular, identification of novel specific tumor antigens and evaluation of most advanced combinatorial strategies could result in unprecedented clinical outcomes with great beneficial effect for HCC patients. The state of the art in immunotherapy strategies for HCC and future perspectives are reported in the present review.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>23714157</pmid><doi>10.1016/j.jhep.2013.05.031</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0168-8278
ispartof Journal of hepatology, 2013-10, Vol.59 (4), p.897-903
issn 0168-8278
1600-0641
language eng
recordid cdi_proquest_miscellaneous_1434744581
source Elsevier
subjects Active immunotherapy
Antigens, Neoplasm - immunology
Cancer vaccine
Cancer Vaccines - immunology
Cancer Vaccines - therapeutic use
Carcinoma, Hepatocellular - immunology
Carcinoma, Hepatocellular - therapy
Combined Modality Therapy
Female
Gastroenterology and Hepatology
Hepatocellular carcinoma
Humans
Liver Neoplasms - immunology
Liver Neoplasms - therapy
Male
Metronomic chemotherapy
Molecular Targeted Therapy
Tumor antigen discovery
Tumor Microenvironment - immunology
Vaccination - methods
Vaccination - trends
title Challenges in cancer vaccine development for hepatocellular carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T23%3A32%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Challenges%20in%20cancer%20vaccine%20development%20for%20hepatocellular%20carcinoma&rft.jtitle=Journal%20of%20hepatology&rft.au=Buonaguro,%20Luigi&rft.date=2013-10-01&rft.volume=59&rft.issue=4&rft.spage=897&rft.epage=903&rft.pages=897-903&rft.issn=0168-8278&rft.eissn=1600-0641&rft_id=info:doi/10.1016/j.jhep.2013.05.031&rft_dat=%3Cproquest_cross%3E1434744581%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c455t-b5200ce9c924cacbc91dff07deafb1587e92adb54d0fab631316fb6f696469273%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1434744581&rft_id=info:pmid/23714157&rfr_iscdi=true